Project description
First-in-class cell therapy for solid tumours
Nearly one third of ovarian cancers develop resistance to chemotherapeutic drugs that contain platinum, such as cisplatin and carboplatin. Funded by the European Innovation Council, the MACOV project aims to address this medical issue by developing a macrophage-based immunotherapeutic approach. The idea is to generate an off-the-shelf product that consists of allogeneic macrophages that carry targeted therapeutics destined for cancer cells. The project will investigate the efficacy of these cells in multiple animal models for platinum-resistant ovarian cancer. Moreover, researchers will study the pharmacokinetics and pharmacodynamics of this cell-based product, and alongside toxicological assessment, they will prepare it for a Phase I clinical trial.
Objective
Resistance to platinum-based chemotherapy is a major clinical challenge in ovarian cancer. About 300,000 women are diagnosed with ovarian cancer each year and the number of deaths is estimated at 180,000 worldwide each year. Ovarian cancer metastasizes early in its development, often before it's diagnosed. Ovarian cancer treatment involves surgery with frontline platinum-based chemotherapy. As many as 15-30% of patients with ovarian cancer have primary platinum-resistant or refractory disease. The recurrence of ovarian cancer is now considered a sign of an incurable disease (it becomes platinum-resistant).
The project MACOV aims to develop an innovative allogeneic, ready-to-use macrophage-based therapy for platinum-resistant ovarian cancer. This is a ground-breaking, first in class therapy that shows very high efficacy in multiple solid tumors of unmet medical need.
These cells are equipped with targeted therapy drugs complexed with the carrier protein ensuring their stability in the carrier cell. The protein-drug complex is transferred specifically to cancer cells. The whole concept of this cell therapy is based on the groundbreaking scientific discoveries of MDC (Macrophage-Drug Conjugate). Two European Research Council (ERC) grants were received to study the molecular basis of the discovered mechanism - in 2016 and 2020. In 2018 this project was selected to be promoted as one of the 10 European projects during ERC 10th Anniversary.
The MACOV project will generate of complete efficacy data package for the pre-clinical development of MDC-735 product, consisting of efficacy in multiple animal models for platinum-resistant ovarian cancer, PK, PD and toxicology study as well as consolidate IP and validate business case. The result of the project will be a validated cell therapy product for platinum-refractory ovarian cancer, tested for effectiveness and ready-to-use for the Phase I clinical trial.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences basic medicine toxicology
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC - HORIZON EIC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2022-TRANSITION-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
01-510 WARSAW
Poland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.